European Organisation for Research and Treatment of Cancer - EORTC
423
21
47
226
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.8%
88 terminated/withdrawn out of 423 trials
72.0%
-14.6% vs industry average
40%
168 trials in Phase 3/4
10%
23 of 226 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (423)
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Role: lead
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Role: lead
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
Role: lead
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Role: lead
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Role: lead
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
Role: collaborator
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Role: lead
Eortc MoBilE Device (EMBED)
Role: lead
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Role: collaborator
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Role: lead
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Role: lead
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
Role: lead
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Role: collaborator
177Lu-DOTATATE for Recurrent Meningioma
Role: lead
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Role: lead
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Role: lead
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Role: lead
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
Role: lead
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Role: lead
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
Role: lead